Phase Bioscience Announces Collaboration with Centocor Research and Development
PhaseBio’s deltaPhase technology offers new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods.
According to PhaseBio, the advantages seen with its process include: increased yields, high throughput and elimination of chromatography steps for final product purification. “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio,” stated Clay B. Thorp, Chairman of the Board, Phase Bioscience, Inc.
Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research.